KALA BIO, Inc.
KALAHealthcare|Biotechnology|US
$0.16
+0.00 (+2.23%)
DCF Value
$40.64
Tangible Book / Share
$121.95
Cash / Share
$97.48
About
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Stock Price
-99.6%(1Y)
1M
-47.4%
3M
-79.2%
6M
-96.1%
YTD
-99.4%
1Y
-99.6%
3Y
-100.0%
5Y
-100.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$3.0M
Employees6 (-84% YoY)
CEOAvi Minkowitz
IPO DateJul 20, 2017
Beta-2.21
52-Week Range$0.1146 – $95.5
Avg Volume1,123,404
ExchangeNASDAQ
Websitekalarx.com
Ownership
Float96.1%
Shares Outstanding19.3M
Recent Insider Trades
Purdy Brendan P.OTHER
Jan 30, 20260 shares
Posen Hillel D.OTHER
Jan 30, 20260 shares
Minkowitz AvrahamOTHER
Jan 30, 20260 shares
Colman Yonatan C.OTHER
Jan 30, 20260 shares
Berger Chaim D.OTHER
Jan 30, 20260 shares
Peers
Recent News
KALA BIO, Inc. (NASDAQ:KALA) Stock Short Interest Report for September
Oct 12, 2026 · defenseworld.net
KALA BIO (NASDAQ:KALA) Stock Falls 0.9% – Time to Sell?
Oct 11, 2026 · defenseworld.net
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Sep 29, 2026 · newsfilecorp.com
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Sep 24, 2026 · globenewswire.com
KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of “Reduce” by Brokerages
Sep 18, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:17 AM